We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tobacco Mosaic Virus Nanoparticle Delivery System Increases Potency of Experimental Anticancer Drug

By LabMedica International staff writers
Posted on 20 Jun 2016
Print article
Image: When packaged inside tobacco mosaic virus nanoparticles, phenanthriplatin is delivered to tumors, where it was shown to be more effective in vivo than an approved platin (Photo courtesy of Case Western Reserve University).
Image: When packaged inside tobacco mosaic virus nanoparticles, phenanthriplatin is delivered to tumors, where it was shown to be more effective in vivo than an approved platin (Photo courtesy of Case Western Reserve University).
A candidate anticancer drug was found to be considerably more potent than standard treatments and this potency was further increased in a mouse model when the drug was delivered by a tobacco mosaic virus (TMV)-based transport system.

The experimental anticancer drug candidate phenanthriplatin (cis-[Pt(NH3)2Cl(phenanthridine)](NO3)), is a cationic monofunctional DNA-binding platinum(II) compound with unusual potency and cellular response profiles that was developed at the Massachusetts Institute of Technology (Cambridge, USA).

Despite being up to 40 times more potent than traditional platin agents when tested directly against cancer cells growing in culture, the compound performed no better than standard platins in mouse models. To enhance the delivery of the drug investigators at Case Western Reserve University (Cleveland, OH, USA) used tobacco mosaic virus (TMV) as a delivery system (designated PhenPt-TMV). TMV forms hollow nanotubes with a polyanionic interior surface. The investigators capitalized on this native structure to develop a one-step phenanthriplatin loading protocol.

They reported in the April 26, 2016, issue of the journal ACS Nano that phenanthriplatin was released from the carrier when subjected to the acidic environment with tumor cells. In vivo tumor delivery and efficacy were confirmed by using a mouse model of triple negative breast cancer. Tumors treated with PhenPt-TMV were four times smaller than tumors treated with free phenanthriplatin or cisplatin, owing to increased accumulation of phenanthriplatin within the tumor tissue.

"We may have found the perfect carrier for this particular drug candidate," said senior author Dr. Nicole Steinmetz, assistant professor of biomedical engineering at Case Western Reserve University. "The long, thin tobacco mosaic virus nanoparticles are naturals for delivering the drug candidate into tumors. Phenanthriplatin is about one nanometer across and, when treated with silver nitrate, has a strong positive charge. It readily enters and binds to the central lining. Inside tumors, the nanoparticles gather inside the lysosomal compartments of cancer cells, where they are, in essence, digested. The pH is much lower than in the circulating blood. The shell deteriorates and releases phenanthriplatin."

Related Links:
Massachusetts Institute of Technology
Case Western Reserve University
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more